Sunday, June 23, 2024

37M Dyspepsia NUD GAD 7 years Metabolic syn WB PaJR

Discharge summary:


Age/Gender
:35 Years/Male

Discharge Type

Admission Date: 29/10/2022 12:11 PM


Diagnosis
GENERALIZED ANXIETY DISORDER GAD
NUD, tinea 

Case History and Clinical Findings
35 yr male came with chief complaints of- Epigastric pain since 5 yrs

HOPI:Patient was apparently asymptomatic 5yrs ago then he developed epigastric pain he went to local hospital 5yrs ago where he was given medication and again after 4 years he presented with loin pain went to local hospital where he was diagnosed with renal calculi and now presented with epigastric pain since 1 month
,insidious in onset ,pricking type,non radiating, reduced after taking food, burning sensation after taking spicy food,relievedaftermedication.-Nofever,vomiting,,diarrhoea 

Past history:Not a known case of DM,HTN, Asthma, Epilepsy,CVA,CAD,TBPresent history:Appetite - NornalDiet-MixedSleep -AdequateBowel and bladder habits -RegularNo addictionsGeneral Examination:Patient is conscious, coherent, co-operativeWell oriented to time, place and person
Moderately built and nourished
-Nopallor,icterus,cyanosis,clubbing,pedaloedema,lymphadenopathy vitals:
pr:87bpm bp:130/80mmhg temp:98.1 rr:14cpm


Systemic Examination:




Abdominal Examination:Inspection:-Shape of abdomen - slightly distended- Umbilicis - Central-All quadrants moving equally with respiration- No scars,sinuses, engorged veins,dilated vesselsPalpation:- No local rise of temperature,no tenderness- No organomegalyAuscultation:-Bowel sounds heardCVS: S1S2 PresentRS: BAE Present,NVBS

Brief course in hospital:

35yr male came  with chief complaints of epigastric painsince 1month, insidious in onset ,pricking type,non radiating, reduced after taking food, burning sensation after taking spicy food,relieved after medication.gastro opinion was taken was advised upper gi endoscopy was done which shows non erosive antral gastritis .ortho opinion was taken advised x ray of foot and knee which appears to be normal.derma opinion was taken for hypopigmented patches, taenia cruris was diagnosed ,topical anti fungals are given,

Investigation

CBP:
HB-13.6 TLC:9,000 RBC:5.13 PLC:2.73


Treatment Given(Enter only Generic Name)


T.PAN 40MG PO/OD
LULIFINE CREAM OD
EBERNATE CREAM OD
T.TECZINE PO/OD


Advice at Discharge
T.PAN 40MG PO/OD X 5 DAYS
T.HIFENAC PO/BDX 5DAYS
T.SHELCAL PO/OD X 30DAYS
T.NEUROKIND PO/OD X 30DAYS
LULIFINE CREAM X 1WEEK AT NIGHT
EBERNATE CREAM X 1WEEK AT MORNING


Follow Up
REVIEW AT GENERAL MEDICINE OP
When to Obtain Urgent Care

 in my own language
SIGNATUREOFPATIENT/ATTENDER SIGNATURE OF PG/INTERNEE SIGNATURE OF ADMINISTRATOR SIGNATURE OF FACULTY


Discharge Date Date:09/11/22 Ward:MEDICALWARD
Unit:6

Recent follow up UDLC dyadic pre PaJR:

[22/06, 00:21] Pt Advocate 37M GAD NUD WB: ๐™Ž๐™ž๐™ง ๐™–๐™ข๐™–๐™ง ๐™‹๐™š๐™ฉ๐™š๐™ง ๐™ฅ๐™–๐™—๐™ก๐™š๐™ข๐™ฉ๐™– ๐™–๐™—๐™–๐™ง ๐™๐™˜๐™๐™š ๐™ฉ๐™–๐™ž ๐™ ๐™–๐™ก๐™ ๐™š ๐™ช๐™จ๐™œ ๐™ง๐™ž๐™ฅ๐™ค๐™ฉ ๐™ ๐™ค๐™ง๐™—๐™ค ๐™ง๐™ž๐™ฅ๐™ค๐™ฉ ๐™ฉ๐™–๐™ ๐™ž ๐™–๐™ฅ๐™ฃ๐™–๐™ ๐™š ๐™ฅ๐™–๐™ฉ๐™๐™–๐™—๐™ค

[22/06, 14:52] BLLM: 5 bochor aager byatha ta aekhon kemon ache?

[22/06, 15:24] Pt Advocate 37M GAD NUD WB: ๐˜ฝ๐™š๐™ฉ๐™๐™–๐™ฉ๐™– ๐™–๐™ ๐™๐™–๐™ฃ ๐™ฃ๐™š๐™ž ๐™ฉ๐™—๐™š ๐™–๐™ก๐™ฅ๐™ค ๐™ ๐™๐™š๐™ก๐™š๐™ž ๐™ฅ๐™š๐™ฉ ๐™ซ๐™ค๐™ง๐™š ๐™…๐™–๐™ฎ ๐™–๐™ง ๐™จ๐™˜๐™ž๐™™๐™ž๐™ฉ๐™ž ๐™๐™–๐™˜๐™š ๐™ก๐™ž๐™ซ๐™–๐™ง๐™š๐™ง ๐™Ÿ๐™–๐™ฎ๐™œ๐™–๐™ฎ ๐™๐™–๐™ก๐™ ๐™– ๐™—๐™š๐™ฉ๐™๐™– ๐™๐™–๐™ฎ ๐™ค ๐™ฉ๐™ค๐™ฎ๐™ก๐™š๐™ฉ๐™š๐™ง ๐™จ๐™ค๐™ข๐™ค๐™ฎ ๐™Ÿ๐™–๐™ก๐™– ๐™๐™ค๐™ฎ

[22/06, 18:23] Pt Advocate 37M GAD NUD WB: ๐™Ž๐™ž๐™ง ๐™–๐™ข๐™–๐™ง ๐™ช๐™จ๐™œ ๐™ง๐™ž๐™ฅ๐™ค๐™ฉ๐™– ๐™ ๐™š๐™ข๐™ค๐™ฃ ๐™–๐™˜๐™๐™š

[22/06, 18:26] BLLM: USG te apnar somosya ta bojhar kotha noi

[23/06, 18:38] Pt Advocate 37M GAD NUD WB: ๐™Ž๐™ž๐™ง ๐™–๐™ ๐™๐™–๐™ฃ ๐™–๐™ข๐™–๐™ง ๐™ ๐™–๐™ง๐™ค๐™ฃ๐™ž๐™ค ๐™ ๐™ž ๐™–๐™˜๐™๐™š

[23/06, 18:42] BLLM: Apnar jonye ekta group toiri kore debo shekhane doinondin janaben apnar khabar plate er chobi ebong ghontai ghontai ki ki korchen anekata jemon ekhane baki ra ki bhabe janacche dekhte paren ๐Ÿ‘‡

[23/06, 18:53] Pt Advocate 37M GAD NUD WB: ๐™Ž๐™ž๐™ง ๐™–๐™ข๐™–๐™ง ๐™ช๐™จ๐™œ ๐™ง๐™ž๐™ฅ๐™ค๐™ฉ๐™– ๐™™๐™š๐™ ๐™๐™š ๐™˜๐™œ๐™š๐™ฃ


[23/06, 18:57] BLLM: ๐Ÿ‘†Aagei dekhe janiyechi

[23/06, 18:58] BLLM: ๐Ÿ‘† Gotokal ghontai ghontai sokal theke raat obdhi ki korechilen janaben ebong kone somoi byatha hoyechilo shetao janaben

Sunday, June 9, 2024

UDLCO : Faces of Semaglutide and it's conversational peer review in journal clubs

UDLCO summary :


New pharmacological intervention with extended indications for diabetes, weight gain as well as heart failure in the form of a novel GLP1 inhibitor recently flying off the shelves has raised eyebrows and the journal club raises certain issues. There is also some discussion around a typical face that Semaglutide produces. 


UDLC transcripts :

Metacognitist metapsych group journal club conversational transcripts logged here earlier :



[4/9, 12:35 AM] Pediatric endo NJ :

 Semaglutide in HFpEF 



[4/9, 8:28 AM] Rakesh Biswas: We left this journal club midway with our students around the question of trying to understand the clinical significance of the statistically significant changes in :

"in the mean KCCQ-CSS as 13.7 points with semaglutide and 6.4 points with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001), and  mean percentage change in body weight as −9.8% with semaglutide and −3.4% with placebo"!

The next step was reviewing all the points in the KCCQ-CSS to understand the clinical significance of it's numbers



[4/9, 8:59 AM] Rakesh Biswas: Would it be possible for you to share the full text. 

I realized that our students had been discussing a full text of an earlier 2022 study published open access but probably ignored this as there was no full text


[4/9, 9:20 AM] Rakesh Biswas: Journal club  conversational critical appraisal and the point where we got stuck shown in the transcripts below :


an observational, retrospective, real-world study on obese outpatients with T2D and chronic HF at the HF Units of Internal Medicine Department at the Hospital Regional Universitario de Mรกlaga in Mรกlaga; the Hospital Costal de Sol, in Marbella; and the Hospital Helicopteros Sanitarios, in Marbella, Spain.

P - total of 136 patients were included ( out patients ) 

I - safety and efficacy of semaglutide as management for obesity in TY2DM and HF. 

C - clinical, laboratory and therapeutic variables of pre and post Semaglutide therapy at 3, 6, 12 months in same patients. 

O - From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p<0.01), a reduction in the proportion of patients with New York Heart Association functional class III (40.4% to 16.2%, p<0.01), and a reduction in N-terminal pro-brain natriuretic peptide levels (969.5 ± 653.5 vs 577.4 ± 322.1 pg/mL, p<0.01). Emergency department visits due to heart failure, hospitalizations due to heart failure, and all-cause hospitalizations also declined. Additionally, significant reductions in glycated hemoglobin (-1.4%) and body weight (-12.7 kilograms) were observed as well as a de-intensification of antidiabetic therapy.


[4/3, 8:42 AM] Sai Charan Kulkarni 2020 KIMS Pg: *primary endpoint* :  was to evaluate the clinical efficacy in the HF health status, as determined by the improvement in the total symptom score on the Spanish version of the Kansas City Cardiomyopathy Questionnaire (KCCQ) (19), reduction in the New York Heart Association (NYHA) classification, and reduction in NT-pro-BNP levels. 

*Secondary outcomes* : included the glycemic efficacy, as determined by the reduction in HbA1c levels and the proportion of patients who achieved good glycemic control (HbA1c <7%) prior to starting semaglutide and at 3, 6, and 12 months; weight loss (changes in body weight, BMI, and waist circumference); de-intensification of T2D treatment (reduction in number of daily glucose-lowering drugs and/or insulin doses) and HF treatment (decline in number of antihypertensive agents, beta-blockers and diuretics); and the safety (adverse drug reactions, need to discontinue semaglutide due to adverse events, 3P-MACE, emergency department visit because of HF decompensation (from one year before initiation), hospitalizations (from one year before initiation), and mortality (from one year before initiation).


[4/3, 8:50 AM] Rakesh Biswas: Can you share the break up of the symptom score so that we can understand how clinically significant are the differences portrayed by the numbers in the total symptom score here :

As in what's the clinical significance between 59.0 ± 24.1 vs 79.9 ± 28.4 points? Will only become clear when we see what those points stand for? 


[4/3, 8:53 AM] Rakesh Biswas: Share the numbers for these :

"Emergency department visits due to heart failure, hospitalizations due to heart failure, and all-cause hospitalizations also declined."

Also numbers for :

How many had a de-intensification of antidiabetic therapy?"


[4/3, 9:12 AM] Sai Charan Kulkarni 2020 KIMS Pg: All numbers shared here sir. 

[4/3, 9:13 AM] Rakesh Biswas: Discuss their clinical significance

[4/3, 9:15 AM] Rakesh Biswas: Where's the division here between the two groups?


[4/3, 9:16 AM] Rakesh Biswas: Oh just realised there's no comparator!! ๐Ÿ˜ฌ๐Ÿง

What's the point?

[4/3, 9:18 AM] Rakesh Biswas: How can frontiers publish such a study without a comparator especially when it's not a qualitative study either providing insights?

[4/3, 9:19 AM] Rakesh Biswas: Let's look for some RCTs for Semaglutide efficacy?

[4/9, 9:41 AM] NJ : @Rakesh: Here you go.

[4/9, 10:35 PM] Rakesh Biswas: Went through this NEJM study full text today thanks to @⁨NJ  and also through the full text of the Kansas City Cardiomyopathy
 questionnaire from 2000 and as suspected there are quite a few issues!


For a start, the questionnaire says it's a 2 week recall and the study evaluates it after a year, which means the patients are simply telling us what happened in the last two weeks, not one year? 

Also what would change with Semaglutide in a year when answering KCCQ questions like the one below ๐Ÿ‘‡

"Heart failure symptoms can worsen for a number of reasons. How sure are you that you know what to do, or whom to call, if your heart failure gets worse?



[4/10, 12:52 AM] NJ : @Rakesh: I am not sure I understand the issues you’re referring to.

KCCQ-CSS is a validated patient reported outcome measure - although it represents a 2-week recall at any time point, it has been shown to be valid, reproducible, and sensitive to clinical changes in patients with systolic dysfunction, HFpEF, and other conditions. 

So, in this case the pre-randomization score can be taken to be representative of the baseline situation, and the end of study score representative of the situation after 52 weeks of treatment. The primary efficacy endpoint is typically assessed at a pre specified discrete time point after a specific period of intervention. 

From that perspective, the use of KCCQ-CSS is appropriate, despite the fact that it was measured at Weeks 20 and 36 too. The time course (Figure 1A) supports the reality of improvement at week 52. 

The same is seen for weight. The trajectory of weight loss (Figure 1B) supports the between-group difference at week 52.

Evolving demand for more and more Semaglutide like drugs: 

From "couch potato to couch carrots" appears to be the current drug development flavor/fervor ๐Ÿ˜…๐Ÿ‘‡

 [5/5, 2:47 AM] +1 (832) Nearly half of Americans  are awaiting prescription for one of these GLP1 agonists 
(market projected to be worth as much as $100 billion by 2030.)
There is lot of bio pharmaceutical investment in this field and science is moving fast to develop new designer molecules with triple agonists ( GLPI , GIP and glucagon/ AI models being used to accelerate drug development 
Amgen has partnered with NIVDIA for drug development/ generative biology allows for the generation of new protein-based drugs that have desired structures and properties based on existing protein data inputs.
We will see flood of GLP dual and triple agonists in next few years . 
April 2024, more than 50 glucagon-like peptide-1 receptor agonists  are in clinical development for type 2 diabetes, obesity, or both. 
Loss of lean body mass and sarcopenia remains concern with GLP- 1 
Few exciting molecules in development , which reduce fat mass and increase muscle mass. No need to exercise, 
Never heard of this before exerkine analogues (peptide that is released during exercise that improves metabolic and muscle function. ) can be synthesized and being developed for obesity, one stop solution for couch potatoes
Azelaprag is one of these drugs undergoing trials. Then there is Class of myostatin inhibitors.
A myostatin inhibitor called taldefgrobep alfa, undergoing trials to weight loss and increased lean tissue.
I believe, research is exploding in the field of obesity/ to its advantage is AI/ generative biology / this is unlikely to fizzle out like cox inhibitors

[5/4, 4:16 AM] +1 (301): Almost all weight reduction drugs have many different side effects reported, but in the prolong duration and long term side effects or complications data buried or under reported. Pharmaceutical industries wrecking money from these products and have to take responsibility for honest open monitoring and provide correct data to the public.



[5/4, 6:01 AM] Endocrinologist NJ: None of these studies looked at hand grip and/or 6-min walk to test muscle strength. 

What I’m saying is that losing muscle (as determined by DEXA) may not be a bad thing, unless there’s loss of strength.  

Talking about just muscle mass w/o data on strength and calling that sarcopenia is not appropriate. And, probably just a gimmick. 

Most of the agents that have been tested for sarcopenia (e.g., age-related sarcopenia) have shown improvements in muscle mass without appreciable improvements in strength.


[5/4, 9:50 AM] Rakesh Biswas: Is Sarcopenia the reason for ozempic face? 



Some of my patients who have given up sugar totally have also shared their before after facial pictures with me that suggests similar facial changes. I would wager the facial changes could be fat reduction. Any review of literature data on this?


[5/4, 10:49 AM] +44: Won't be surprised in few years time , this will be like cox inhibitor drugs and withdrawn






October 28 update:

Lancet review:

[27/10, 20:23] Rakesh Biswas: "The crucial roles of skeletal muscle have come to the forefront of public attention due to data on the use of GLP-1 receptor agonists, which are effective for weight loss, but can cause substantial muscle loss. Studies suggest muscle loss with these medications (as indicated by decreases in fat-free mass [FFM]) ranges from 25% to 39% of the total weight lost over 36–72 weeks.2 This substantial muscle loss can be largely attributed to the magnitude of weight loss, rather than by an independent effect of GLP-1 receptor agonists, although this hypothesis must be tested. By comparison, non-pharmacological caloric restriction studies with smaller magnitudes of weight loss result in 10–30% FFM losses.3 In context, on an annual basis, the decline in muscle mass with GLP-1 receptor agonists is several times greater than what would be expected from age-related muscle loss (0·8% per year based on 8% muscle loss per decade from ages 40–70 years)."

Unquote

https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00272-9/abstract?dgcid=raven_jbs_etoc_email


[27/10, 21:03] Pediatric Endocrinologist NJ: However, muscle strength has not been assessed with GLP-1 RAs-induced weight loss. 
Loss of muscle mass + decrease in muscle function = sarcopenia. 
Age-related loss of muscle mass is sarcopenia, because it is associated with loss of muscle function. 
Weight-loss meds associated decrease in muscle mass may or may not be sarcopenia. Well designed studies are needed… first, to see if objective decreases in muscle function occur, and then to assess if similar/matched loss of muscle from other weight loss modalities (e.g., bariatric surgery) cause similar loss in muscle function.

November 2024 Update on another GLP1 inhibitor used again for heart failure perhaps to make the cut as demonstrated in sglt2 inhibitor! 

Conversational Transcripts:

[17/11, 06:54] r: This is yesterday's hot cake burning social media ๐Ÿ‘‡



[17/11, 06:58] r: And here are the influencers


[17/11, 07:00] rb: 


[17/11, 07:04]rb: @⁨Meta AI⁩ can you access the full text and analyse this study data in the PICO format taking care to share the absolute numbers and not relative percentages (luckily it's catching up with the current journal articles too and this added prompt may hopefully become redundant soon). If you can't access the full text through the URL below ๐Ÿ‘‡


then I can share the full text PDF although I'm not sure if you have begun reading PDF in the WhatsApp interface
[17/11, 07:05] Meta AI: Unfortunately, I remain unable to access the study directly through the URL, but I can still assist.

To proceed, please provide:

1. Study title
2. Relevant text or data excerpts (you can copy-paste)
3. Specific analysis requests (e.g., PICO format, focus areas)

This will enable me to provide the desired analysis.

If you share the full text, I'll ensure to:

- Extract absolute numbers (not relative percentages)
- Analyze in PICO format
    1. Population (P)
    2. Intervention (I)
    3. Comparator (C)
    4. Outcomes (O)

Let's begin!


[17/11, 07:22] rb : I used Google LM (free version) to do the PICO prompt I gave meta AI after first trying the free version of ChatGPT which didn't work (for free)!๐Ÿ‘‡

## PICO Analysis of Tirzepatide Study Data

Here is a PICO analysis of the tirzepatide study data from the provided excerpt from the New England Journal of Medicine, taking care to use absolute numbers instead of percentages:

* **Population (P):** The study included **731** patients with:
    * Chronic heart failure (New York Heart Association class II to IV)
    * A left ventricular ejection fraction of at least 50%
    * A body mass index (BMI) of at least 30 (obesity)
    * A 6-minute walk distance of between 100 and 425 m
    * A Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) of 80 or lower

* **Intervention (I):** The intervention group received tirzepatide subcutaneously, starting at a dose of 2.5 mg per week and increasing by 2.5 mg every 4 weeks (if tolerated) up to a maximum dose of 15 mg per week. **364** patients were assigned to the tirzepatide group.

* **Comparison (C):** The comparison group received a placebo. **367** patients were assigned to the placebo group.

* **Outcomes (O):** The study assessed two primary outcomes:
    * **Composite of adjudicated death from cardiovascular causes or a worsening heart-failure event:** This occurred in **36 patients** in the tirzepatide group and **56 patients** in the placebo group.
        * **Worsening heart-failure events** occurred in **29 patients** in the tirzepatide group and **52 patients** in the placebo group.
        * **Adjudicated death from cardiovascular causes** occurred in **8 patients** in the tirzepatide group and **5 patients** in the placebo group.
    * **Change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS):** At 52 weeks, the mean change in the KCCQ-CSS was 19.5 points in the tirzepatide group and 12.7 points in the placebo group.

The study also assessed several key secondary outcomes, including:

* **Change in the 6-minute walk distance at 52 weeks:** The mean increase in the 6-minute walk distance was **26.0 m** in the tirzepatide group and **10.1 m** in the placebo group.
* **Percent change in body weight at 52 weeks:** The mean percent change in body weight was **-13.9%** in the tirzepatide group and **-2.2%** in the placebo group.
* **Percent change in the high-sensitivity CRP level at 52 weeks:** The mean percent decrease in the high-sensitivity CRP level was **-38.8%** in the tirzepatide group and **-5.9%** in the placebo group.

The median duration of follow-up for the study was **104 weeks**. The authors concluded that tirzepatide reduced the risk of cardiovascular death or worsening heart failure and improved health status in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.


[17/11, 07:23] : It appears that google LM may not suffer from the same kind of number dyslexia as meta AI! Will need to play with it more



Tuesday, June 4, 2024

Dr Nupur Sarkar CV

 MBBS, AIIMS, New Delhi 1996


MD Pediatrics AIIMS, New Delhi 2000


 

Senior Resident 2000-2001

Asst Prof 2002-2008

Associate Prof 2008-2014

Faculty Of Homeopathy 2023



Friday, May 31, 2024

UDLCO : Fever ProJR qualitative thematic analysis beginnings

UDLCO summary :


Project principal investigators PIs collecting data regularly for each of the current 10 projects need to qualitatively thematically analyze on a case by case basis each of the 50-60 odd cases collected over last two years since their projects began. The conversational transcripts below describe a UDLC driven thematic analysis using human users that is perhaps quite akin to how multiple nodes in an artificial neural network would optimise input data toward an acceptable learning output after few iterations through deeper layers of nodes. The human user driven nodes performed comparably well at present and learning points from the first two thematic analysis on two cases is summarized  below after every UDLC activity centered around each patient. 


Please check out the linked primary data case report forms collated by Anahita that are still pending thematic analysis at the bottom of this page.

Previous work up links on this project serially placed from past to current:

Origins:

1) Resolving undifferentiated fever diagnostic uncertainty 2000-2002

2) Fever pattern recognition as a tool to optimise antibiotic stewardship in the community curtailing it's overuse in common viral fevers with diagnostic uncertainty


3) Follow up to the Bangalore study in a Bhopal PG thesis 


4) Optimising clinical complexity in fever 
Narketpally:



Conversational transcripts:

Summary learning points from the first case logged by ET Dr Aneef here : https://feverprojr.blogspot.com/2024/05/75m-unclassified-fever.html

Theme diagnostic uncertainty :

The 75M patient's sepsis apparently resolved after administration of antibiotics chosen for an uncertain (retrospectively)/certain (prospectively to some actors during March 2024)as part of their urological localization of the sepsis."

Again in days to weeks, he showed another localization in the lungs and antibiotics were again targeted to another uncertain (retrospectively) /certain (prospectively) organism isolated from the lungs which didn't appear to resolve and he died and it's currently uncertain from the overall timeline if he died due to the organisms or due to his associated organ failures (comorbidities in heart, brain, kidneys) that contributed to the clinical complexity. 




[5/29, 10:49 AM] Kims Med Pg 2021 Nishitha: IP numbers 
202420849
202417326
202415062
202400500
202340363
202309595
202328687
202234910
202250631
202252367
20242030
202407866
202357639
202346995
202434778
202241122
202310413
202254447
202225168
202418444
202315122
202311545
202305865
202301161
202400780
202345350
202228310
202324679
202241628 
202300561
202224060
202413981
202239691
202409834
202417690
202415982
202313499
202402512
202243893
202243570
202241128
202414578
[5/29, 10:49 AM] Kims Med Pg 2021 Nishitha: Enteric fever 
202300561
202224060
202413981
Scrub typhus 
202239691
Unclassified 
202409834
202417690
202415982
202313499
202402512
202243893
202243570
202241128
202414578
[5/29, 10:50 AM] Kims Med Pg 2021 Nishitha: Leptospirosis 
202434778
202241122
202310413
202254447
202225168
SLE 
202418444
202315122
202311545
202305865
202301161
202400780
202345350
202228310
[5/29, 10:50 AM] Kims Med Pg 2021 Nishitha: Malaria 
202420849
202417326
202415062
202400500
202340363
202309595
202328687
202234910
202250631
202252367
Fungal 
20242030
202407866
202357639
202346995
202324679
202241628
[5/29, 12:24 PM] Kims Med Pg 2021 Nishitha: https://nishithaalla95.blogspot.com/2022/07/fever-dissertation.html
[5/29, 1:05 PM] Rakesh Biswas: Share the learning themes from this case everyone
[5/29, 1:05 PM] Rakesh Biswas: Before we move to the next
[5/30, 8:06 PM] Aneef Elective May 2024: Ma'am can you kindly share if there is ET culture results? It's mentioned that it had been sent but I am unable to locate the result.
[5/30, 8:08 PM] Aneef Elective May 2024: Sir in this case, I feel there are some information gaps that need to be addressed. 

Such as ET results, the precipitating event for developing sudden Resp Failure.

With fever chart update
[5/30, 11:19 PM] Kims Med Pg 2021 Nishitha: Viral- 
202409018
202226311
202404563
202415266
202407401
202405209
202404330
202404334
202408699
202239576
202233683
202407923
202341050

Culture positive-
202422642
202419709
202249038

Unclassified-
202419545
[5/31, 1:55 AM] Kims Med Pg 2021 Nishitha: Its written in the next line itself that enterobacter was isolated from ET culture
[5/31, 8:36 AM] Rakesh Biswas: This is the first case being analyzed?
[5/31, 8:37 AM] Aneef Elective May 2024: Yes sir
[5/31, 8:40 AM] Aneef Elective May 2024: Oh! Thank you ma'am for pointing it our
[5/31, 8:41 AM] Rakesh Biswas: The date of discharge in your case report mentions 5/4 while the available fever chart shows 8/4 and that too very high grade spikes! 

How do you explain that @⁨Kims Med Pg 2021 Nishitha⁩ ?
[5/31, 8:44 AM] Kims Med Pg 2021 Nishitha: Maybe it was typed wrong by our interns who made that discharge summary sir
I will check and get back to u
[5/31, 8:50 AM] Kims Med Pg 2021 Nishitha: Found it out sir
His frst case sheet was discharged and second case sheet was opened
But we continued the fever chart
[5/31, 8:53 AM] Rakesh Biswas: Yes but when was he discharged and was he discharged with those high fever spikes? How can we say then in his discharge that he recovered?
[5/31, 9:00 AM] Kims Med Pg 2021 Nishitha: Frst case sheet was discharged due to arogya sree issues sir so it was kept as recovered
Second case sheet was opened on the same day but They went on LAMA on 9th sir so there is no fever chart after 8th and pt went home with high grade fever spikes sir
[5/31, 9:06 AM] Rakesh Biswas: And what happened to the patient after that?
[5/31, 9:09 AM] Rakesh Biswas: It's written :

"ET TUBE CULTURE WAS SENT

ENTEROBACTER SPECIES WAS DETECTED"

Which date? 

What drug sensitivity tests were run and what was it susceptible to?

Was it pathogenic for the patient? If so did he have a ventilator associated pneumonia VAP? Please share his chest X-ray asap
[5/31, 9:45 AM] Rakesh Biswas: The PI's not actively analyzing each of their 50 project patient participants by the steps detailed earlier will get an opportunity of 6  more months to do it
[5/31, 9:55 AM] Kims Med Pg 2021 Nishitha: He had low grade fever spikes at home for 2 days sir and fever subsided but patient suddenly died on 28/04/2024
[5/31, 10:01 AM] Aneef Elective May 2024: Wow! Thank you ma'am
[5/31, 10:01 AM] Aneef Elective May 2024: Is it acinetobacter ?
[5/31, 10:03 AM] Aneef Elective May 2024: I believe if it is an extended spectrum resistant acinetobacter, it was most probably VAP
[5/31, 10:06 AM] Kims Med Pg 2021 Nishitha: 06/04/2024
[5/31, 10:06 AM] Kims Med Pg 2021 Nishitha: His post intubation chest xray sir
[5/31, 10:19 AM] Rakesh Biswas: How many days post intubation? 

Why can't this be cardiogenic pulmonary edema? @⁨Aneef Elective May 2024⁩
[5/31, 10:20 AM] Kims Med Pg 2021 Nishitha: Immediately after his intubation sir
[5/31, 10:21 AM] Rakesh Biswas: It can't be VAP then? 

What's the definition of VAP @⁨Aneef Elective May 2024⁩ ?

[5/31, 10:22 AM] Rakesh Biswas: Can the organism decide the pathology? Prove it to me that this wasn't a commensal. Search for commensal Acinetobacter in the engine and share what you learn


[5/31, 10:35 AM] Aneef Elective May 2024: Sir my assumption was based on its wide resistance

[5/31, 10:41 AM] Rakesh Biswas: Why should someone who is tough automatically be designated criminal without a fair trial?


All we need to know about acinetobacter sir. I am currently trying to find relevant information from this very long study ๐Ÿ˜…
[5/31, 10:43 AM] Aneef Elective May 2024: Sir please correct me if I am wrong. Because the blood is sterile, it shows that the infection was local uncomplicated UTI. 

In addition, the patients overall picture and mortality too derives its root from a primary respiratory infection


[5/31, 10:44 AM] Rakesh Biswas: So as per @⁨Kims Med Pg 2021 Nishitha⁩'s data on the chest X-ray shared above, the shadows were already there on day 1 of intubation and hence it doesn't satisfy the VAP definition?


[5/31, 10:48 AM] Aneef Elective May 2024: "In general, Acinetobacter spp. are found in wet environments, including moist soil/mud, wetlands, ponds, water treatment plants, fish farms, wastewater, and even seawater (3). These environmental strains often harbor antibiotic resistance mechanisms, including carbapenemases and extended-spectrum ฮฒ-lactamases (ESBLs) (3), and may thus serve as important environmental reservoirs for resistance elements that transform into clinically relevant strains."

Al Atrouni A, Joly-Guillou ML, Hamze M, Kempf M. 2016. Reservoirs of non-baumannii Acinetobacter species. Front Microbiol 7:49. doi: 10.3389/fmicb.2016.00049.


[5/31, 10:51 AM] Aneef Elective May 2024: Sir interestingly, the environmental form itself is Multi drug resistant ๐Ÿ˜…


[5/31, 10:55 AM] Rakesh Biswas: What primary respiratory infection? 

What is the incidence of urine cultures positive uti also testing positive in blood culture?


[5/31, 10:56 AM] Rakesh Biswas: Why shouldn't it be? 

Why should someone who is tough automatically be designated criminal without a fair trial?


[5/31, 11:17 AM] Aneef Elective May 2024: Background

To effectively treat sepsis and urinary tract infection (UTI), blood and urine cultures should be used appropriately and relative to incidences of bacteremia and bacteriuria. This study aimed to investigate the use of blood and urine cultures and incidences of bacteremia and bacteriuria in a hospital in Thailand.

Methods

Medical records of patients admitted from 2016 to 2018 were randomly selected and data in the records were anonymously extracted for investigation.

Results

From 12 000 records, data on blood and urine cultures were extracted from 9%  and 4% of them, respectively. *The negative rate of blood culture was 87.48%*. Bacteremia was detected in 10.22%. The positive rate of urine culture was 27.38%

Conclusions
A high negative rate of blood culture may result not only from its low sensitivity but also from liberal test use to identify sepsis in some conditions. Improper urine collection is the main problem with use of urine culture.

Reference



[5/31, 11:25 AM] Rakesh Biswas: ๐Ÿ‘๐Ÿ‘

Hope this clarifies


[5/31, 11:27 AM] Rakesh Biswas: Share the "fever project" learning points from this patient as per your initial objectives and let's quickly close this case and move to the next?


[5/31, 12:00 PM] Kims Med Pg 2021 Nishitha: Sir in this case we have diagnostic uncertainity and therapeutic uncertainity of his fever

Is it because of the E. Coli from urine or acenetobacter from ET and what should be treated

Leaning point here is at frst the antibiotic we started was sensitive to e. Coli and his fever spikes subsided but after intubation was done the organism isolated was resistant to the same antibiotic and his fever spikes were persistent and were high grade

[5/31, 12:29 PM] Kims Med Pg 2021 Nishitha: So we cannot treat every organism with the same antibiotic or we shouldnt give patient antibiotics which are of no use or for which they are resistant

[5/31, 12:47 PM] Kims Med Pg 2021 Nishitha: Even after we got culture reports and changing the antibiotic ultimately patient outcome (death) didn't change sir
This is the therapeutic uncertainty in this case

[5/31, 12:51 PM] Kims Med Pg 2021 Nishitha: Diagnostic uncertainity is whether the patient had his fever spikes due to isolated E. Coli or acenetobacter or any other cause

[5/31, 12:55 PM] Rakesh Biswas: I can see that we are now somewhat on the right track. 

Can the above learning points be expressed in a better written manner @⁨Chandana Kims Med PG⁩ @⁨Aneef Elective May 2024⁩ ?


[5/31, 1:42 PM] Chandana Kims Med PG: I have a doubt sir.

RESOLVING DIAGNOSTIC AND THERAPEUTIC UNCERTAINTIES AND IMPROVING OUTCOMES IN PATIENTS WITH UNDIFFERENTIATED FEVER

What do we mean by undifferentiated fever?

Going by literature , undifferentiated fever is when there is no localizing signs of infection.(ex-dengue,other viral fevers, malaria,typhoid,leptospira etc)
 
Why are we including urosepsis and aspiration pneumonia case?

@⁨Kims Med Pg 2021 Nishitha⁩
[5/31, 1:50 PM] Kims Med Pg 2021 Nishitha: His urosepsis resolved with our treatment mam
I included this case because he has no symptoms of aspiration pneumonia but has fever spikes
After chest xray was taken and et culture was positive we got to know the cause

[5/31, 1:53 PM] Chandana Kims Med PG: Yes exactly..when we evaluate and find out a cause or localise a fever it doesnt become undifferentiated fever.


[5/31, 2:00 PM] Rakesh Biswas: Good point!

[5/31, 1:55 PM] Chandana Kims Med PG: The term acute undifferentiated febrile illness (AUFI) connotes fever of <14 days duration without any evidence of organ or system specific aetiology


[5/31, 1:58 PM] Aneef Elective May 2024: Does Acute decompensated heart failure have fever as a symptom?

[5/31, 1:59 PM] Aneef Elective May 2024: To bring it to context, This patient has been on diuretics lasix 40 mg and has history of  HTN and DM and CVA


[5/31, 2:01 PM] Rakesh Biswas: Comorbidities adding to clinical complexity

[5/31, 2:02 PM] Chandana Kims Med PG: Acute decompensated heart failure (ADHF) typically does not present with fever as a primary symptom. The common symptoms of ADHF include:Shortness of breath(dyspnea), particularly when lying down (orthopnea) or during physical activity, Swelling(edema),palpitations , cough, and reduced exercise tolerance.
However, fever in a patient with ADHF might indicate an underlying infection or other complicating condition. For example: co existing UTI, pneumonia or myocarditis or endocarditis

[5/31, 2:03 PM] Aneef Elective May 2024: Thank you ma'am for this elaborate explanation

[5/31, 2:09 PM] Rakesh Biswas: To rephrase it again : I guess you meant,

"His sepsis apparently resolved after administration of antibiotics chosen for an uncertain/certain urological localization."

However he showed another localization in the lungs and antibiotics were again targeted to another uncertain/certain organism isolated from the lungs which didn't appear to resolve and he died and it's uncertain if he died due to the organisms or due to his associated organ failures that contributed to the clinical complexity. 

@⁨Chandana Kims Med PG⁩ Does this now sound like a good contender to your second paper as the first here ๐Ÿ‘‡

"Understanding clinical complexity in organisms and organ systems


[5/31, 2:12 PM] Chandana Kims Med PG: Yes sir

[5/31, 2:14 PM] Rakesh Biswas: Let's quickly dig out the organismal and organ system complexities in the other ProJRs asap

[5/31, 2:14 PM] Aneef Elective May 2024: Yes sir

Second case :

UDLC summary :

A 45F woman with lowbackache and CKD since many years and recently sepsis brewing for 1 month, presented with undifferentiated fever and encephalopathy that was attributed to sepsis.  In our recently published past analysis of CKD sepsis cases, we  showed that patients with chronic kidney disease sepsis and lowbackache had vertebral-spinal pathologies due to poor infection control measures during haemodialysis. All these patients were young with a long history of secondary hypertension. https://pubmed.ncbi.nlm.nih.gov/37335625/.
In this patient,given the clinical presentation overlap, both septic and uremic encephalopathy can present with altered mental status, making differential diagnosis challenging.

Recognition and treatment of potential sepsis are essential, even in the absence of clear localization of infection.

Negative cultures do not exclude sepsis, clinical judgment and continued observation are vital.

The lack of improvement in mental status and persistent fever despite adequate hemodialysis suggests a diagnosis other than uremic encephalopathy, supporting septic encephalopathy.




Conversational transcripts :



[5/31, 6:59 PM] Rakesh Biswas: Is date of admission really 24/4??

Did she spend 1 month here??


[5/31, 7:00 PM] Rakesh Biswas: Is this the second thesis patient for discussion among your 50 patients?


[5/31, 7:45 PM] Chandana KIMS 2020 SR: I think it is the admission date on case sheet (opened for 10 day care dailysis) but she became bad someday in between and came to icu . When was she admitted to icu? @⁨Kims Med Pg 2021 Nishitha⁩


[5/31, 8:00 PM] Kims Med Pg 2021 Nishitha: Sir she was admitted on 24/4 for maintenence hemodialysis and was coming only for dialysis once a week

Then she had high grade fever we advuced admission but they didnt want to stay back after dialysis and took her back home

Then when she came for hemodialysis she suddenly went into altered sensorium and was admitted to icu on 11/05 night sir


[5/31, 8:50 PM] Kims Med Pg 2021 Nishitha: 

Fever could not be localized in this case, and cultures came back negative. Despite daily hemodialysis for 7 days, the patient did not improve and continued to have fever spikes and altered sensorium, making septic encephalopathy highly likely rather than uremic encephalopathy and also one day in between when her counts came down her gcs improved and she was able to talK few words and was oriented but again the next day counts again increased and her gcs and sensorium came down

Later, the patient succumbed to death after leaving the hospital against medical advice.

Learning points-

Clinical Presentation Overlap,both septic and uremic encephalopathy can present with altered mental status, making differential diagnosis challenging.
Recognising and treatment of potential sepsis are essential, even in the absence of clear localization of infection.

Negative cultures do not exclude sepsis, clinical judgment and continued observation are vital.

The lack of improvement in mental status and persistent fever despite adequate hemodialysis suggests a diagnosis other than uremic encephalopathy, supporting septic encephalopathy.

Bedsores can introduce new infections 

Uncertainty-

Diagnostic-Negative blood cultures

Non localised (undifferentiated) fever

Therapeutic-

Persistent fever and altered sensorium despite daily hemodialysis and antibiotics for 7 days strongly suggest septic encephalopathy, as uremic symptoms should improve with dialysis. Possibility of drug resistant organism is there.But it also maybe due to middle molecules even though her urea was normal

Bore sore development later made the diagnosis more uncertain as it can also contribute to fever(although it developed later)

[5/31, 8:59 PM] Rakesh Biswas: Wow! ๐Ÿ‘๐Ÿ‘

That's very rapid progress since the first case this morning! 

Can you share some relevant review of literature to septic encephalopathy and similar case reports of the same in the background of dialysis patients. 

Again @⁨Chandana KIMS 2020 SR⁩ , Karnati Vaishnavi and Aditya's last paper was largely around the complexity of managing sepsis in our dialysis patients

Raw fever patient data in case report forms from 2022-24 narketpally thesis: